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Hematologic parameters predicting a response to
oral iron therapy in chronic inflammation
In anemic patients with chronic inflammatory condi-
tions, the assessment of iron status and the selection of
those who may benefit from iron therapy frequently pres-
ents diagnostic challenges.1,2 Traditional biochemical iron
parameters, such as ferritin, serum iron and transferrin, are
affected by inflammation making them less suitable indi-
cators.3
Recently, iron parameters have become available that
provide direct information on iron availability for erythro-
poiesis: the central iron regulatory hormone hepcidin4-7
and the hemoglobin content of reticulocytes and erythro-
cytes (Ret-He and RBC-He).8-11 We hypothesized that
changes in these functional iron parameters shortly after
start of iron supplements may predict an increase in hemo-
globin in a longer course of iron supplements in patients
with chronic inflammation. 
Forty adult patients diagnosed with a chronic rheumatic
disease and anemia were selected during routine visits in
2012 at the rheumatology outpatient clinic of the Radboud
University Medical Center, Nijmegen, the Netherlands.
Anemia was defined as a hemoglobin concentration below
12.1 g/dL for males and below 11.3 g/dL for female,
respectively. Exclusion criteria were signs of hemolysis
(increased levels of lactate dehydrogenase), end stage renal
disease, liver disease (two times the upper limit of the ref-
erence value of alanine aminotransaminase (ALT)), known
malignancies, vitamin B12 or folic acid deficiency, use of
iron supplements, erythropoietin or medications with
potential drug interactions with the iron supplements and
a blood transfusion in the previous two months. Patients’
characteristics, including age, sex, medication and the type
of inflammatory condition, were recorded at baseline
(Table 1). 
Rheumatoid arthritis was the most common diagnosis
(58%) and disease-modifying drugs (60%) and non-
steroidal anti-inflammatory drugs (53%) were frequently
used. Ethical clearance was granted by the Radboud
University Medical Center, and written informed consent
was obtained from all participants. 
Ferrofumarate 200 mg BD (130 mg of elemental iron per
day) was prescribed during six weeks. Blood samples were
collected at baseline, after one, two and six weeks.
Responders to iron therapy were defined as patients with
an increase in hemoglobin of at least 0.81 g/dL (0.5
mmol/L) after six weeks of oral iron supplementation.  The
hemoglobin content parameters were measured on a
Sysmex XE5000 analyer (Sysmex Corporation). Serum
hepcidin-25 measurements were performed using a com-
bination of weak cation exchange chromatography and
time-of-flight mass spectrometry as described previously.12
The other iron parameters were determined as previously
described.7
At week 6, 2 patients had withdrawn from the study:
one at personal request and one because of pneumonia.
Sixteen of 38 participants who completed the study were
responders. Responders had significantly lower base-line
values of ferritin, hepcidin, Ret-He and RBC-He and trans-
ferrin saturation (TS), and higher total iron binding capac-
ity (TIBC), soluble transferrin receptor (sTfR) and its ratio
to log ferritin (sTfR-index) levels in comparison to non-
responders (Figure 1). Levels of CRP were similar between
the groups. At one week of iron therapy, responders had a
significantly larger increase in Ret-He level (0.28 ± 0.26
fmol) compared to the non-responders (0.18 ±0.04 fmol)
(P<0.000) and a larger change in reticulocyte numbers
(Figure 1). There was no increase in Ret-He between
weeks 1 and 2. In contrast, there were no significant dif-
ferences in the change in hepcidin levels at either time
point. Moreover, responders had significantly larger
increases in serum iron and TS values at one week with a
concurrent significant decline in sTfR-index levels after
two weeks of iron therapy. 
Regression analyses were applied to predict the change
in hemoglobin and the outcome of being a responder after
six weeks of iron therapy. The strongest association with
the hemoglobin response at six weeks was found for base-
line RBC-He, ferritin, Ret-He and hepcidin levels, and the
increase after one week in values of TS, serum iron, Ret-
He, reticulocytes and ferritin, both in descending order
(Table 2).
The diagnostic performance of parameters was subse-
quently assessed using Receiver Operating Characteristic
(ROC) analyses. The change in values of serum iron, TS,
Ret-He and reticulocytes at one week had the highest
areas under the curve (AUC) (Table 2). At one week, an
increase in serum iron and Ret-He of more than 4 mmol/L
and 0.11 fmol, respectively, had a sensitivity of 80% and
81%, and specificity of 91% and 86%, respectively. At
baseline, values of ferritin, hepcidin and the sTfR-index
had the highest AUC values, but the change in these
parameters at week 1 was not a useful predictor of the
response to iron therapy. The combination of the change
in values of Ret-He and TS at one week provided the high-
est discriminatory power (AUC 0.906, SE 0.054; P<0.000). 
Overall, the increase after one week of oral iron therapy
in Ret-He, TS, serum iron level and the reticulocyte count
best predicted an increase in hemoglobin level of at least
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Table 1. Base-line characteristics of study population. 
Variable                                                                   Total 
                                                                             (n=40)
Female, n. (%)                                                                   26 (65)
Age, mean (SD), y                                                             62 (15)
Condition, n. (%)                                                                     
Rheumatoid arthritis                                                    23 (57.5)
Spondylarthropathy                                                          2 (5)
PMR                                                                                    3 (7.5)
Arthritis ns                                                                        6 (15)
Other auto-immune disease                                         6 (15)
Drugs*, n. (%)                                                                          
NSAID                                                                               21 (52.5)
Glucocorticosteroids                                                     20 (50)
DMARD                                                                              24 (60)
Biological                                                                          7 (17.5)
Combination of 2                                                            16 (40)
Combination of 3 or more                                            9 (22.5)
Hemoglobin, mean (SD), g/dL                                              
Male                                                                                 11.8 (0.9)
Female                                                                            11.3 (0.7)
CRP, median (IQR), mg/L                                          9.5 (4.3-20.3)
Creatinine, mean (SD), µmol/L                                  75.9 (20.9)
ALT, mean (SD), U/L                                                      29.2 (15.2)
Folic acid, mean (SD), nmol/L                                    22.7 (13.8)
Vitamin B12, mean (SD), pmol/L                             350.7 (164.0)
*Drugs related to inflammatory condition. SD: standard deviation; PMR: polymyalgia
rheumatica; ns: non specified; NSAID: non-steroidal anti-inflammatory drugs;




Figure 1. Box and whisker plots of iron status parameters at baseline and after one and two weeks of iron supplementation for responders (white)
and non- responders (gray). *represent significant P- values of t-test comparisons or Mann Whitney tests between responders and non- responders.
#represent significant P-values of paired samples t-test or Wilcoxon Signed Rank test comparisons between baseline and week one or week two
of responders and non- responders. P-values xxx ≤ 0.001, xx ≤0.01, x <0.05. For abbreviations and SI conversion factors see Table 2. Reference
values (when applicable): Ret- He 2.00- 2.41 fmoles, reticulocytes 20-80 109/L, hepcidin < 14.7 (males), < 12.3 nM (premenopausal females),
<15.6 nM (postmenopausal women), iron 10-30 µmol/L, TIBC 45-80 µmol/L, ferritin 15-180 µg/L (males), 6-80 µg/L (premenopausal females),
15-280 µg/L (postmenopausal women), sTfR 0.76-1.76 mg/L.
Table 2. Prediction of the response to six weeks of iron therapy. 
Linear regression¶                                            At baseline                                   Change at 1 week                                 Change at 2 weeks
                                                                            (n=38)                                                (n=38)                                                    (n=37)
Reticulocytes, 109/L                                                            n.s.                                                 31.1 %; 2.94, P<0.001                                       23.7 %; 2.15, P 0.001
Ret-He, fmol                                                         40.5 %; -6.2, P<0.001                                   24.9 %; 4.4, P 0.001                                          19.8 %; 4.1, P 0.003
RBC-He, fmol*                                                     52.8 %; -7.9, P<0.001                                  22.5 %; 22.9, P 0.005                                       41.5 %; 21.8, P<0.001
Hepcidin, nmol/l                                                  35.4 %; -.56, P<0.001                                                  ns                                                                        ns
Iron, µmol/L                                                          16.8 %; -1.3, P 0.006                                  47.5%; 1.04, P <0.001                                        21.9 %;0.77, P 0.002
TIBC, µmol/L                                                         22.8 %; 4.5, P 0.008                                                   ns                                                                        ns
TS, %                                                                       25.4 %; -1.4, P 0.001                                 48.9 %; 1.04, P <0.001                                       23.7 %; 0.76, P 0.001
Ferritin, µg/L                                                        41.4 %; -.80, P <0.001                                 17.8 %; 0.93, P 0.006                                         20.1 %; 1.0, P 0.003
sTfR, mg/L                                                               24.1 %; 1.8, P 0.001                                                    ns                                                                        ns
sTfR-index, mg/ µg                                              43.9%; 1.5, P <0.001                                   16.0 %; -2.6, P 0.009                                        23.7 %; -3.2, P 0.001
ROC analyses§                                                                        
Reticulocytes, 109/L                                                             ns                                                 §0.807±.075; P 0.001                                        0.783±.090; P 0.004
Ret-He, fmol                                                           0.720±.088; P 0.02                                    0.824± .080; P 0.001                                        0.783±.080; P 0.004
RBC-He, fmol*                                                       0.771±.087; P 0.01                                                    ns                                                          0.765±.010; P 0.02
Hepcidin, nmol/l                                                    0.808±.075; P 0.001                                                   ns                                                                        ns
Iron, µmol/L                                                                         ns                                                   0.894±.058; P 0.000                                          0.786±.080; P 0.003
TIBC, µmol/L                                                         0.774±.079; P 0.004                                                   ns                                                                        ns
TS, %                                                                                       ns                                                   0.889±.058; P 0.000                                          0.783±.079; P 0.004
Ferritin, µg/L                                                         0.828±.067; P 0.001                                                   ns                                                         0.762±.081; P 0.007
sTfR, mg/L                                                               0.727±.090; P 0.02                                                    ns                                                                        ns
sTfR-index, mg/µg                                                0.801±.079; P 0.002                                                   ns                                                          0.716±.089; P 0.03
Table shows the (i) linear regression model to predict the change in hemoglobin at week 6 and (ii) ROC analyses to assess the  chance of being responder of base-line param-
eters and their relative changes after one or two weeks of iron therapy.  ¶Depicted are the adjusted squared R (x 100%), the unstandardized B- coefficient and P- value, calcu-
lated on log- transformed variables. The B- coefficient expresses the (relative) change in hemoglobin concentration after six weeks iron therapy that is associated with a 1-unit
change in the independent variable. §Depicted are: the area under the curve, standard error and corresponding P- value. *n: 32, n: 36 and n: 34, respectively.  Ret-He: reticulo-
cyte- hemoglobin content; ns: non-significant; RBC-He: erythrocyte- hemoglobin content; TIBC: total iron binding capacity; TS: transferrin saturation; sTfR: soluble transferrin
receptor; sTfR-index: sTfR/ log ferritin; ROC: receiver operator curve; SI conversion factors: To convert hemoglobin to grams per liter, multiply by 10.0; to convert Ret-He, RBC-
He to pg, multiply by 16.1. 
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0.81 g/dL at week 6 of iron therapy. Base-line values of fer-
ritin, hepcidin, sTfR-index and RBC-He also predicted the
hematopoietic response, but to a lesser degree.
There are still no established diagnostic criteria to iden-
tify absolute iron deficiency in patients with inflammation.
Our study design is unique in that we evaluated the pre-
dictive value of iron status indicators in response to oral
iron therapy in patients with rheumatic diseases. The
value of Ret-He as a screening tool for ID has been recog-
nized before7,13 and our current findings support its role as
a marker for iron responsiveness. This may be of particular
diagnostic value when results of conventional iron status
parameters are inconclusive. The advantage of reticulocyte
count and hemoglobin content parameters is that their
results can be obtained quickly and extra blood tests are
not required. However, before these hemoglobin content
parameters can be widely implemented, additional
research into the various patients’ groups and clinician
education and training is required.14
Our study was designed with minimal inclusion criteria
in order to maximize the generalizability of our results.
Potential limitations are the self-reported drug compliance:
i) the possible interaction of iron absorption with frequent-
ly used proton pump inhibitors (specific intake instructions
were given); ii) the relatively modest degree of inflamma-
tion in our study population; and, finally, iii) the duration
of iron treatment in our study may not have been suffi-
cient to replete iron stores in all patients.
In conclusion, in anemic patients with a chronic
rheumatologic disease, the increase in hemoglobin con-
centration to six weeks of iron supplementation was best
predicted by the change in Ret-He, TS and serum iron lev-
els and the reticulocyte count after one week of oral iron
therapy. Prospective analysis of these parameters is espe-
cially useful when initial values of iron status indicators,
such as a normal or elevated serum ferritin level, cannot be
used to reliably exclude iron deficiency. 
Susanne van Santen,1,2 Quirijn de Mast,1 Janine D. Oosting,3
Annelies van Ede,4 Dorine W. Swinkels,2
and André J.A.M. van der Ven1
1Department of General Internal Medicine; 2Department of
Laboratory Medicine, Laboratory of Genetic, Endocrine and
Metabolic diseases; 3Department of Laboratory Medicine,
Laboratory of Clinical Chemistry; and 4Department of




Key words: hematologic parameters, oral iron therapy, chronic
inflammation, response.
Information on authorship, contributions, and financial & other dis-
closures was provided by the authors and is available with the online
version of this article at www.haematologica.org.
References
1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med.
2005;352(10):1011-23.
2. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and
management of iron-restricted erythropoiesis. Blood 2010;116(23):
4754-61.
3. Northrop-Clewes CA. Interpreting indicators of iron status during
an acute phase response-lessons from malaria and human immun-
odeficiency virus. Ann Clin Biochem. 2008;45(1):18-32.
4. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human
iron disorders: diagnostic implications. Clin Chem. 2011;57(12):
1650-69.
5. Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, Molineux G.
Serum hepcidin but not prohepcidin may be an effective marker for
anemia of inflammation. Blood Cells Mol Dis. 2010;45(3):238-45.
6. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al.
Regulation of iron homeostasis in anemia of chronic disease and
iron deficiency anemia: diagnostic and therapeutic implications.
Blood 2009;113(21):5277-86.
7. van Santen S, van Dongen-Lases EC, de Vegt F, et al. Hepcidin and
hemoglobin content parameters in the diagnosis of iron deficiency
in rheumatoid arthritis patients with anemia. Arthritis Rheum.
2011;63(12):3672-80.
8. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the
reticulocyte hemoglobin content in the diagnosis of iron deficiency.
Blood 2002;99(4):1489-91.
9. Thomas C, Thomas L. Biochemical markers and hematologic
indices in the diagnosis of functional iron deficiency. Clin Chem.
2002;48(7):1066-76.
10. Ullrich C, Wu A, Armsby C, Rieber S, Wingerter S, Brugnara C, et
al. Screening healthy infants for iron deficiency using reticulocyte
hemoglobin content. JAMA. 2005;294(8):924-30.
11. Brugnara C, Mohandas N. Red cell indices in classification and
treatment of anemias: from M.M. Wintrobes's original 1934 classi-
fication to the third millennium. Curr Opin Hematol. 2013;20(3):
222-30.
12. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N,
Pickkers P, van Ede AE, et al. Immunochemical and mass-spectrom-
etry-based serum hepcidin assays for iron metabolism disorders.
Clin Chem. 2010;56(10):1570-9.
13. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T,
Cavill I. Guideline for the laboratory diagnosis of functional iron
deficiency. Br J Haematol. 2013;161(5):639-48.
14. Piva E, Brugnara C, Chiandetti L, Plebani M. Automated reticulocyte
counting: state of the art and clinical applications in the evaluation
of erythropoiesis. Clin Chem Lab Med. 2010;48(10):1369-80.
haematologica 2014; 99:e173
LETTERS TO THE EDITOR
